RenovoRx, Inc. 8-K

What Happened
RenovoRx, Inc. filed an 8‑K (Mar 27, 2026) announcing that its Board formally appointed Ramtin Agah, M.D., currently Chief Medical Officer and Chairman of the Board, to the newly created role of Executive Chairman effective February 27, 2026. On March 24, 2026 Dr. Agah accepted an offer letter that amends and replaces certain prior consulting terms and sets employment terms beginning January 1, 2026.

Key Details

• Annualized base salary: $450,000, based on a minimum of 30 hours/week, payable semi‑monthly.
• Annual discretionary bonus: up to 40% of base salary (first bonus payable in 2027 for 2026 performance).
• Equity: eligible for annual option grants and other awards (e.g., RSUs) under the company’s 2021 Omnibus Equity Incentive Plan, subject to plan/grant terms and vesting.
• Other terms: employment is at‑will; an Amended and Restated Change in Control and Severance Agreement dated November 10, 2025 remains in effect.

Why It Matters
This filing formalizes leadership consolidation—Dr. Agah will hold both executive and board leadership roles—which may affect strategic direction and management continuity. For investors, the filing provides concrete compensation figures (salary, bonus potential, equity eligibility) that impact RenovoRx’s executive cost structure and incentive alignment. The continued change‑in‑control/severance agreement and equity awards are relevant to shareholder dilution and potential payouts in corporate transactions.